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Spinal cord injury (SCI) is a devastating disease which poses health problems in 
human and veterinary medicine. SCI causes neurological disability, with loss of 
motor, sensory and autonomic function. This study investigated the efficacy of local 
treatment with IKVAV-peptide on spinal cord regeneration following compression 
injury at T12 vertebra in Balb-c mice. IKVAV-peptide is a membrane spanning 
peptide known to have a long half-life and the peptide motif IKVAV. Thirty Blab-c 
female mice were used. Hemilaminectomy was performed at T12 and spinal cords 
were compressed using extradural application of a 24 g modified aneurysm clip for 1 
min in the treatment groups. After 24 hours mice were treated with one of 4 different 
treatments including isoleucine-lysine-valine-alanine-valaine(IKVAV), IKVAV-
peptide, peptide and mannitol (vehicle). Functional improvement was assessed every 
day using Basso, Beattie, Bresnahan (BBB) Locomotor Rating Scale. 28 days later, 
the mice were euthanized, and spinal cord segments were studied histologically. 
Statistical analysis, one-way and two-way analysis of variance (ANOVA) and linear 
regression model were used to measure some parameters and describe the outcome  
 
after SCI. Over a 4weeks period, IKVAV-peptide group demonstrated statistical and 
histological evidence of cellular reconstruction and behavioral improvement. The 
BBB score in the IKVAV-peptide group increased by 5.4 (25%) points, the IKVAV 
and peptide groups by approximately 1 point (5%) and the mannitol group by 4 points 
(19%).  The number of protoplasmic astrocytes in the IKVAV-peptide group was 
significantly increased compared to IKVAV, mannitol and normal groups but not with 
the peptide group (p<0.001). Neuron and muscle bundle size were also increased 
significantly (p<0.05 and p<0.007, resp.) in the IKVAV-peptide group compared to 
other treatment groups. The treated control groups showed cellular and gross damages 
including neuron inactivation and muscle atrophy, gliosis and inability of movement. 
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Chapter I 
1.  Introduction 
1.1 Spinal cord anatomy 
1.1.1Gross anatomy  
The spinal cord is a flattened cylindrical structure which is bilaterally 
symmetrical. It is enclosed in three membranes or meninges; these are, from without 
inwards, the dura, arachnoid, and pia matters. Each spinal nerve is joined to its 
segment of the cord by a number of roots and rootlets grouped as dorsal and ventral 
roots. Spinal nerve rootlets enter the cord dorsally and leave ventrally. Each spinal 
nerve is divided into dorsal and ventral branches: the dorsal branch innervates epaxial 
muscles and ventral branch innervates hypaxial muscles. In cross section, the spinal 
cord exhibits a butterfly-shaped grayish tan inner substance, the gray matter (roughly 
in the shape of an “H”) surrounding the central canal, and a whitish peripheral 
substance, white matter. The central canal is lined by a columnar, ciliated epithelium, 
the ependym, which is encircled by a zone consisting primarily of neuroglia but also 
containing a few nerve cells and fibers. During life it contains cerebrospinal fluid. The 
white matter contains myelinated and unmyelinated ascending and descending tracts 
(axons), the gray matter contains interneurons and their cell bodies, as well as the cell 
bodies of the lower motor neurons and neuroglia. Synapses occur only in the gray 
matter. The gray matter contains a ventral and dorsal horn, and the connection portion 
that is divided by the central canal into a dorsal and ventral commissure. The ventral2 
 
horn contains motor cell bodies that innervate skeletal muscles for reflex and 
voluntary activity. The dorsal horn contains cell bodies of sensory neurons, 
pseudounipolar type which bring sensory information from the limbs and organs [1-3]. 
1.1.2 Functional neuroanatomy 
The nervous system along with the endocrine and immune systems and the 
sensory organs, is responsible for receiving various stimuli and coordinating the 
reactions of the organism. The stimuli cause impulses that are registered, transmitted, 
processed and answered in the form of passive or active reactions. Thus, the nervous 
system enables the body to interact, adapt and react to the environment. A network of 
nerves connects all organs of the body. This network is comprised of nerve tissue, 
which can be classified according to function or morphology. This classification is 
purely didactic; in fact the nervous system acts as a single functional unit. 
Morphological classification divides the nervous system according to location into 
central and a peripheral system. The central nervous system (CNS) includes the brain 
and the spinal cord. Complex systems of neurons are dependent on junctions capable 
of transmitting nerve impulses between neurons, muscle cells and glandular cells. 
These gaps between the various cells involved in nerve signaling are termed synapses 
and play an extremely important role in the transmission of impulses [4]. The function 
of nervous system is to enable the organism to respond to internal and external stimuli 
in order to survive. Stimuli are perceived by specific receptors that may be organized 3 
 
into sense organs (e.g., ear, eye, olfactory mucosa) or dispersed as individual 
elements. In summary the functional unit of the nervous system is the stimulus-
receptor apparatus. It consists of five elements that are outlined here: (1) Receptors 
and (2) afferent neurons constitute the input limb. (3) The central nervous system 
ensures adequate processing of the information provided. The output is mediated 
through (4) efferent neurons and (5) effecter organs. Afferent and efferent elements 
belong to the peripheral nervous system (PNS) as opposed to the brain and spinal cord, 
which together form the central nervous system (CNS) or neuraxis.  
The physiochemical process of impulse transmission on neurons is always the same 
regardless of the information being conveyed [5]. There are three typical spinal 
reflexes which are clinically important including: myotactic reflex, withdrawal reflex 
and cutaneous trunci reflex [4]. 
1.2 Spinal cord embryology 
The nervous system originates from a dorsal neural tube, and the neural crest, 
formed from surface ectoderm. The neural tube, whose walls begin as a layer of 
neuroepithelial cells, becomes the CNS. The neuroepithelial cells then begin a three-
phase process of differentiation, which occurs largely in the second month of the fetal 
development. They proliferate to produce the appropriate number of cells needed for 
nervous system development. Once they reach characteristic positions in the forming 
CNS, they differentiate into neuroblasts [6]. The mantle layer becomes the gray matter 
of the spinal cord, which consists primarily of neuronal cell bodies. Due to differential 
migrations of immature neurons, the mantle layer becomes shaped like a butterfly with 4 
 
prominent dorsal and ventral gray columns (horns). Initially the gray columns are 
uniform along the entire length of the spinal cord. However, as the limbs develop the 
columns at the corresponding axial levels become significantly enlarged to 
accommodate neuron cell bodies for each limb. The presence of a greater number of 
neuronal cell bodies in these regions is the result of degeneration of immature neurons 
in nonlimb-innervating regions. Most of the cells in regions of the spinal cord without 
adjacent limbs die because they fail to form viable contacts with developing limb 
muscle tissue. Also, at the thoracic level (T₁ through L₄), immature neurons migrate 
dorsomedially out of the ventral motor columns and form the intermediate gray 
columns. The intermediate gray column contains the neuronal cell bodies of the 
sympathetic neurons. The marginal layer of the spinal cord is commonly referred to as 
white matter, so named because of the appearance of myelinated axons. This outer 
layer contains tracts of ascending (projecting cranially) and descending (projecting 
caudally) axons that are grouped together in bundles called funiculi [7]. 
Approximately 100 billion neurons are present in the CNS, including the interneurons 
and the perikaryons of the motor neurons from the body’s cerebrospinal (somatic) 
nerve system. The neurons are highly specialized structurally and functionally and 
have lost their ability to divide. New neurons develop from precursor cells, the 
neuroblasts only. Once a neuron is lost, it can not be replaced. With intensive training, 
the loss of neuronal function due to small injuries cannot be fully regained by 
neogenesis of the original neuron network but some function can be return using 
collateral neurons [4]. 5 
 
 
1.3 Spinal cord histology 
1.3.1 Normal spinal cord histology 
A basic function of the nervous system is communication. The central nervous 
system (CNS) consists of the brain and spinal cord and contains the nerve cells, or 
neurons, and a host of supporting cells called the neuroglia [8]. Neuroglia provide 
protection for delicate neuronal processes, electrical insulation for nerve cell bodies 
and their processes and metabolic exchange pathways between the vascular system 
and the neurons of the nervous system [1]. Nerve impulses pass to and from the CNS 
over long neuronal processes called axons. The peripheral nervous system (PNS) 
comprises all of these processes which travel in cranial and spinal nerves and related 
clusters of outlying neurons known as ganglia. Neurons exhibit an astonishing variety 
of forms, but each has a cell body, or soma, consisting of a nucleus and its surrounding 
cytoplasm, the perikaryon [8]. The cell body of a neuron has characteristics of a 
protein- producing cell. The cytoplasm reveals abundant rough endoplasmic reticulum 
(RER) and free ribosomes when observed with the transmission electron microscope 
(TEM). At the light microscopic level, the basophilic materials which consist of free 
ribosomes and RER appear as small bodies, Nissl bodies. The cytoplasm also contains 
numerous mitochondria, a large perinuclear Golgi apparatus, lysosomes, microtubules, 
neurofilaments, transport vesicles, and inclusions. The neuron cell body usually has 
several radiating processes called dendrites and a single long slender process, the 6 
 
axon. As expected of cells active in protein synthesis, the Golgi apparatus is prominent 
in all neurons. In electron micrographs, Golgi (a loose network of wavy strands) is 
seen as flat cisternae, often slightly dilated at their ends. It concentrates and slightly 
modifies proteins synthesized in the granular endoplasmic reticulum. The motor 
neuron, together with the muscle fibers it innervates, is called a motor unit. Each 
motor nerve fiber branches to supply many muscle fibers. It is generally accepted that 
nerve cells do not divide; however in some areas of the brain neural stem cells are 
present and are able to differentiate and replace damaged nerve cells [1]. 
1.3.2 Neuroglia 
These are not merely mechanically supportive cells but are metabolically 
active elements that assist nerve cells in performing their integrative and 
communicative functions. These cells consist of astrocytes, oligodendrocytes, and 
microgliocytes. Unlike neurons, glial cells do not seem to play a direct role in neural 
communications. They respond passively to electrical currents and do not generate 
impulses [8]. 
1.3.3 Astrocytes 
The star-shaped glial cells called astrocytes which are classified into two types, 
protoplasmic and fibrous.  These cells provide physical and metabolic support for the 
neurons of the CNS. Protoplasmic astrocytes, which are found mainly in the gray 
matter of the CNS, have numerous, short, branching cytoplasmic processes. Fibrous 
astrocytes are found mainly in the white matter but also in some regions of the 7 
 
preventricular gray matter. They have long thin processes that branch infrequently. 
Astrocytes have an important role in homeostasis in the CNS. Astrocytes are closely 
associated with neurons to support and modulate their activities. It is now thought that 
astrocytes play a role in the movement of metabolites and wastes to and from neurons 
and regulate ionic concentrations in the intercellular compartment, thus maintaining 
the microenvironment and modulating activities of the neurons. They also have a role 
in maintaining tight junctions of the capillaries that form the blood-brain barrier. In 
addition, astrocytes provide a covering for the “bare areas” of myelinated axons, e.g., 
at the nodes of Ranvier and at synapses, but they do not form myelin. They may 
confine neurotransmitters to the synaptic cleft and may remove excess 
neurotransmitters by pinocytosis. Protoplasmic astrocytes at the brain and spinal cord 
surfaces extend their processes to the basal lamina of the pia mater to form the glia 
limitans, a relatively impermeable barrier surrounding the CNS. Ependymal cells form 
the epithelium-like lining of the fluid-filled cavities in the CNS. They form a single 
layer of cuboidal-to-columnar cells that have the morphological characteristics of 
fluid-transporting cells [1, 8]. 
1.3.4 Histopathology of the spinal cord following trauma 
Severe injury to the CNS commonly results in permanent, crippling deficits for 
the remainder of the patient’s life. The apparent inability of the CNS to regenerate and 
reconstitute fiber tracts that have been interrupted (in contrast to the reasonable 
efficiency with which this can occur in the peripheral system) has both fascinated and 8 
 
frustrated clinicians and investigators for decades. It appears that the milieu of the 
brain and spinal cord is inhibitory to axonal regrowth; whereas the same nerve fibers 
extend perfectly well if surgically directed into PNS environment through using the 
scaffold. Astrocytes have previously been considered one element antagonistic to CNS 
repair, but recent investigations point to myelin membrane proteins as important 
sources of neurite growth inhibitions. In the presence of monoclonal antibodies that 
neutralize these proteins or in newborn rats which are irradiated to produce a zone of 
hypomyelination, central axonal regrowth can occur. The injuries to the brain and 
spinal cord produced by trauma vary considerably, depending upon three factors: the 
severity, speed and duration. Acute, explosive injury, as with a sudden intervertebral 
disk prolapse, may produce hemorrhage, edema and ischemia; gray matter is more 
sensitive to such injuries than is white matter. If the spinal cord is acutely damaged, 
leukocytes (mainly neutrophils) enter the damaged tissue in response to chemotactic 
signals within 3 to 6 hours. Blood monocyte-derived mononuclear macrophages are 
evident by the third day, and the neutrophilic influx wans by day 5. Cell death in the 
gray matter may be evident by 4 hours, but the area if necrosis progressively expands 
for a few days. In some cases, the whole spinal cord is necrotic, maintained in situ by 
a meningeal sleeve. The tissue liquefies, becoming soft and paste-like. Less dramatic 
lesions produce central cystic cavities. From the level of the spinal cord injury, a core 
of necrosis may extend cranially and caudally, typically in the base of the dorsal 
funiculi. Isolated areas of necrotic tissue, removed from the immediate point of 
impact, probably reflect regions of ischemia following post-traumatic secondary injury 9 
 
to blood vessels. Chromatolysis of ventral horn neurons occurs as a response to injury 
to the proximal segment of their axons and is called the axonal reaction. Reactive 
astrocytes may contain immunoglobulins, apparently sequestered following blood-
brain barrier disruption.  
Acute, traumatic spinal cord injury is mediated by primary and secondary 
mechanisms. The primary event is the mechanical injury to the tissue, which may 
include compression, distraction and laceration. Secondary changes are the 
interruption to normal vascular perfusion, as well as such factors as electrolyte shifts, 
excitotoxic mechanism of neuronal damage and free radical damage to cells and DNA. 
There is experimental evidence of very early axoplasmic and myelin changes, which 
may reflect calcium-mediated events that precede vascular insufficiency. A cascade of 
further mediators of tissue degeneration which appears later includes: leukocyte 
products, prostaglandins, leukotrienes, free radicals, and excitotoxins. This has 
prompted the use of variety of pharmacological antagonists in attempts to improve the 
management of acute spinal cord trauma. Acute spinal cord injury results in a 
significant reduction in spinal cord blood flow, which contributes to post-traumatic 
ischemia [9]. 
1.4 Neurophysiology 
Neurons are highly responsive to stimuli. This response is called the action 
potential (nerve impulse) and it underlies virtually all functional activities of the 
nervous system [6]. 10 
 
 
1.4.1 Normal cell populations and their roles in the spinal cord 
We often think of the spinal cord as being only the conduit for signals from the 
periphery of the body to the brain or in the opposite direction from the brain back to 
the body. But the spinal cord has many other highly organized functions, for instance, 
neuronal circuits in the cord can cause: walking movements, reflexes that withdraw 
portions of the body from painful objects, reflexes that stiffen the legs to support the 
body against gravity, and reflexes that control local blood vessels, gastrointestinal 
movements, or urinary excretion [10]. The nervous system is the master controlling 
and communicating system of the body [6]. The billions of neurons, also called nerve 
cells, are the structural units of the nervous system. They are highly specialized cells 
that conduct messages in the form of nerve impulses from one part of the body to 
another. Besides their ability to conduct nerve impulses, neurons have some other 
special characteristics. They have extreme longevity. Given good nutrition, neurons 
can function optimally for a lifetime (over 100 years). They are largely amitotic. As 
neurons assume their roles as communicating links of the nervous system, they lose 
their ability to divide. We pay a high price for this neuron feature because they can not 
replace themselves if destroyed. They have an exceptionally high metabolic rate and 
require continuous and abundant supplies of oxygen and glucose. Neurons can not 
survive for more than a few minutes without oxygen [6]. Glia, are important in the 
normal functioning of the nervous system. For example, glia are involved in potassium 11 
 
ion buffering; they provide pathways for neuronal migration during development and 
for axonal guidance during regeneration. They release cytokines in disease processes 
and proliferate or hypertrophy following injury. While they do not participate directly 
in the propagation of nerve impulses, they are involved in Ca ion buffering and 
neurotransmitter reuptake. As a result of injury, astrocytes tend to enlarge and 
proliferate. This process is known as gliosis and results in a glial scar [11].  
1.4.2 Spinal cord injury 
The spinal cord is the major pathway through which nervous signals pass 
between the brain and the body. Therefore spinal cord injury (SCI) results in an 
interruption of these pathways and loss of many bodily functions [12]. SCI, results 
from sudden or sustained trauma or progressive neurodegeneration [13].  
 Since traumatic injury of the central nervous system results in formation of 
scar tissue and axon-growth inhibitory molecules, SCI was believed to be irremediable 
[12, 14]. However, extensive basic and clinical research during the past years have 
demonstrated complex processes underlying the SCI which has provided the basic 
information for developing the promising therapies for this devastating disease [12, 
15]. 
1.4.2.1 Spinal cord response to injury 
Some tissues of the body retain the ability to form new cells from existing 
precursors during the life of the animal, but the nervous system is severely limited in 12 
 
this respect. In general, there is very little generation of new nerve cells once 
development is completed. This is, of course, the main reason why injuries to the 
nervous system have such devastating effects [11]. 
1.4.2.2 Response of neurons to injury 
1-Degeneration, which means that the portion of a nerve fiber distal to a site of 
injury degenerates because of interrupted axonal transport. The cell body of an injured 
nerve swells, its nucleus moves peripherally, and there is loss of Nissl substances, 
called chromatolysis. 2-Scar tissue formation which derives from proliferating glial 
cells that are considered to prevent regeneration [1]. 
1.4.3 Spinal cord injury at molecular and cellular level 
Prevention of SCI and treatment of SCI disabilities are goals that can be 
reached by understanding the pathophysiological changes after injury [16]. Currently, 
the pathophysiology of acute SCI is separated into primary and secondary mechanisms 
[17]. After mechanical damage (primary mechanism) to the spinal cord which leads to 
immediate hemorrhage and rapid cell death, a secondary cascade occurs. This cascade 
causes multiple reactions within the body including ischemia, disarrangement of ion 
concentrations, excitotoxicity, reactive oxygen species, inflammation, apoptosis and 
scar formation over weeks to months [18, 19]. The biological response to a spinal cord 
injury is branched into three phases that follow a definite but partially overlapping 
temporal sequence: acute (seconds to minutes after the injury), secondary (minutes to 
weeks after the injury), and chronic (months to years after the injury) [19].  13 
 
1.4.4 Spinal cord injury: Primary and secondary physiological effects of trauma 
to the spinal cord 
1.4.4.1 Acute phase  
In the acute phase, primary damage occurs as a direct result of trauma such as 
contusion, compression, or laceration leading to immediate physical and biochemical 
cellular alterations and marked by systemic as well as local events. These include 
systemic hypotension, spinal shock, vasospasm, ischemia, plasma membrane 
compromise, derangements in ionic homeostasis, and accumulation of 
neurotransmitters [17, 20].  The primary injury damages both upper and lower motor 
neurons and disrupts motor, sensory and autonomic (including cardiac output, vascular 
tone, and respiration) functions [13]. 
1.4.4.2 Secondary phase 
Pathophysiology processes occurring in the secondary injury phase are rapidly 
influenced in response to the primary injury in an attempt to homeostatically control 
and minimize the damage. These processes are paradoxically and largely responsible 
for exacerbating the initial damage and creating an inhibitory milieu, which prevents 
endogenous efforts of repair, regeneration, and remyelination [13]. Great effort has 
been made to understand the pathophysiological changes underlying SCI in the hope 
of developing neuroprotective strategies and preventing disability. Despite its 
heterogeneous causes, SCI evolves into secondary damage affecting apparently spared 
areas, magnifying the disability and amplifying neurodegeneration. The challenge is to 
clarify why and when such damage occurs. SCI causes not only neuronal and 14 
 
oligodendroglial cell death, but also induces microglial-associated inflammatory 
responses and reactive astrogliosis. The latter alterations contribute to tissue loss and 
glial scar formation. A key mechanism responsible for secondary injury after trauma is 
increased microglial proliferation and associated activation reflected by production of 
pro-inflammatory cytokines and neurotoxic molecules. In parallel, astrocytes move 
away from the center of the lesion, become hypertrophic, proliferate, and up-regulate 
the expression of Glial Fibrous Acidic Protein (GFAP). Hypertrophic astrocytes are 
the major cellular component of the glial scar, which is considered a physical and 
molecular barrier to CNS regeneration. Moreover, reactive astrocytes also produce 
several classes of growth inhibitory molecules, including the family of extracellular 
matrix molecules, known as chondroitin sulphate proteoglycans, which inhibit both in 
vitro and in vivo axonal regeneration. Considerable evidence indicates that preventing 
and/or reducing the inhibitory environment of the glial scar provides a better 
environment for neurons to regenerate. Current knowledge on the role of cell cycle 
events in SCI is derived mainly from rodent SCI models. Up-regulation of cell cycle-
related proteins occurs in both neurons and glia after SCI may contribute to secondary 
damage cascades [21]. The secondary injury is a cascade of cellular and molecular 
events that intensify the initial damage. The secondary phase features a continuity of 
some events from the acute phase –disruption of vasculature and increased 
permeability of the blood-spinal cord barrier, electrolyte shifts, edema, and necrotic 
cell death - as well as novel ones, including the formation of free radicals, delayed 
calcium influx, immune system response or and inflammation, and apoptotic cell 15 
 
death. These mechanisms are interconnected in a self- propagating cycle that 
perpetuates each other once initiated by trauma [20, 22]. The secondary injury starts 
minutes after primary insult and can lasts up to weeks after injury. Extracellular 
glutamate levels are known to increase transiently within the first 3h after SCI, with a 
likely second wave of glutamate release 2–3days after injury, probably due to delayed 
myelin destruction that compromises nearby axon integrity. The early phase comprises 
vasogenic and cytotoxic edema, necrosis, excitotoxicity, early demyelination, and 
systemic events like hypotension (2–48h). Later, macrophage infiltration and 
initiation of glial scar occur. Within 2weeks/6months, glial scarring continues 
together with intraspinal cyst formation. Even later, profound pathological changes 
affect spinal networks through Wallerian degeneration, demyelination, and aberrant 
plasticity with circuit rewiring leading to dysfunction like chronic pain and spasticity. 
The molecular cell-death pathways of SCI (and their effectors) remain largely elusive. 
This condition makes it difficult to identify the best time window for satisfactory 
treatment of acute SCI with the aim of limiting (or even preventing) secondary 
damage. Nonetheless, the consensus is that the time to introduce effective 
neuroprotective strategies after SCI is short, probably restricted to the first hours after 
injury, in analogy with a similar situation for the brain. Studies of brain and spinal 
injuries support the theory that the central nervous system (CNS) responds to a lesion 
in an archetypal fashion, regardless of the insult, and that similar pathological 
pathways and cell-death mechanisms may operate in the brain and spinal cord [23-28].16 
 
  
 
Figure 1.1. Schematic view of potential interactions of IgG with the neuro inflammatory 
response following SCI.  
 
The above schematic diagram represents how the infiltration of microglia and 
leukocytes could exacerbate the initial damage. Microglia and leukocytes are recruited 
to the injury epicenter where they produce neurotoxic substances that cause neuronal 
and oligodendrocytic cell death in the secondary injury cascade. IgG has the potential 
to reduce the extent of secondary damage by interacting with microglia and leukocytes 
in the following mechanism: (1) inhibit microglia activation and reduce pro-17 
 
inflammatory cytokine production, (2) inhibit leukocyte recruitment to the injury 
epicenter following SCI by acting on endothelial cells, and (3) inhibit leukocyte 
activation by upregulation of the inhibitory FcγIIB receptor. BBB (blood-brain 
barrier), LIF (leukemia inhibitory factor), ROS (reactive oxygen species), NOS 
(nitrous oxide synthase), MMPs (matrix-metalloproteinases) [23]. The end result of 
the primary and secondary mechanism events is the considerable loss of cells, 
cavitations, and the formation of a glial scar [13].  
1.4.4.3 Inflammatory response 
The inflammatory response is crucial for the clearance of cellular debris, but 
inflammatory molecules and the inflammatory cascade might contribute to inhibition 
of regeneration of surviving neurons. In addition, over activation of the inflammatory 
response can destroy normal tissue which can result in further loss of function 
following SCI [23]. In the injured spinal cord, microglial cells, immediately after 
injury, secrete pro-inflammatory cytokines, including interleukin (IL)-1β, interleukin-
6, and tumor necrosis factor-α (TNF-α), all of which increase the extent of 
inflammation. However, in the acute phase of SCI, immune reactive cells can damage 
healthy tissues by releasing pro-inflammatory cytokines, reactive oxygen species 
(ROS), and matrix-metalloproteinases [29-31].  In addition to pro-inflammatory 
cytokines, the injured site also has anti-inflammatory cytokine transforming growth 
factor-β (TGFβ). The treatment of SCI rats with TGF-beta reduces lesion volume by 
50% at 48 h and this is associated with decreased accumulation of mononuclear 18 
 
phagocytes in and around the injury site. This reduction of mononuclear phagocyte 
numbers around the site of trauma would reduce their contribution to secondary injury 
[32]. 
1.5 Spinal cord injury complications 
1.5.1 Vascular mechanisms and complications 
Identification of cardiovascular complications after acute SCI is essential to 
minimize adverse outcomes and to optimize recovery [33]. Normal spinal cord is 
required for suitable autonomic control of different viscera and organs including the 
heart and blood vessels [33]. The role of the vascular mechanisms which have been 
obtained from many different angiography methods from a variety of models of the 
acute SCI in several species support the theory and the hypothesis that posttraumatic 
ischemia is a key mechanism and important secondary mechanism of SCI [34]. Major 
cardiovascular complications in the acute stage following SCI include, orthostatic 
hypotension, heart rate abnormalities and venous thromboembolism [33, 35-38]. 
1.5.2 Urinary complications 
Control of the lower urinary tract (LUT) is a coordination of the urinary 
bladder and urethral sphincter, which both are under the control of peripheral and 
different levels of the central nervous system. Injuries and diseases such as SCI affect 
the neuronal regulation of LUT by interruption of ascending and descending 
connection fibers between spinal cord and supra spinal center. In most cases, SCI 19 
 
results in a period of bladder areflexia and dysfunction followed by emergence of 
neurogenic detrusor over reactivity [39, 40]. 
1.5.3 Muscle dysfunction 
It has generally been accepted that muscles that are paralyzed as a result of 
spinal cord injuries undergo atrophy and develop less force. Muscle atrophy, a 
reduction in the size and/or number of muscle fibers, may be present as denervation 
atrophy or disuse atrophy [41]. Denervation atrophy is an outcome from injury to 
motor neurons of the spinal cord or to the motor nerves in the ventral roots through 
which they exit. Disuse atrophy is a result of loss of muscle activation due to 
disruption to the central and segmental synaptic drive onto the surviving spinal motor 
neurons which occurs during most SCI in humans [42]. 
1.5.4 Gastrointestinal complications 
Bowel problems occur in 27% to 62% of patients with spinal cord injuries 
(SCI), most commonly constipation, distention, abdominal pain, rectal bleeding, 
hemorrhoids, bowel accidents, and autonomic hyperreflexia. The acute abdomen, with 
a mortality of 9.5%, does not present with rigidity or absent bowel sounds but rather 
with dull/poorly-localized pain, vomiting, or restlessness, with tenderness, fever, and 
leukocytosis in up to 50% of patients. Fecal impaction may present with anorexia and 
nausea [43]. 
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1.6 Incidence of spinal cord injury  
According to a study initiated by the Christopher & Dana Reeve Foundation, 
approximately 1.9% of the U.S. population, or some 5,596,000 people, reported some 
form of paralysis based on the functional definition used in the survey. Approximately 
0.4% of the U.S. population or some 1,275,000 people reported being paralyzed due to 
a spinal cord injury. It means that we all know someone -- a brother, sister, friend, 
neighbor, or colleague -- living with paralysis [44-46]. Approximately 12,000 new 
cases in the USA are reported each year, and the average medical cost for a patient 
with SCI can be up to $10 million. Besides the financial charge, patients with SCI and 
their relatives are involved with the physical, emotional, and social effects of this 
debilitating condition [23]. Although many studies are focusing on different molecular 
mechanisms to prevent further problem and dysfunction following SCI as well as 
methods to improve recovery following SCI, there is no evidence that the incidence of 
SCI is declining [34]. 
1.7 Targets for intervention in spinal cord injury 
Targets of therapies for SCI to improve function can be simplified into a list: 
1) reduction of edema and free radical production, 2) rescue of neural tissue at risk of 
dying in secondary processes such as damage by abnormally high extracellular 
glutamate concentrations, 3) control of inflammation by anti-inflammatory agents, 4) 
rescue of neuronal/glial populations at risk of continued apoptosis, 5) repair of 
demyelination and conduction deficits; 6) promotion of neurite growth through 21 
 
improved extracellular environment, 7) cell replacement therapies, 8) efforts to bridge 
the gap with transplantation approaches, 9) efforts to retrain and relearn motor tasks, 
10) restoration of lost function by electrical stimulation, such as bladder and bowel 
function or hand function, retrain the brain by aggressive physical therapy and 11) 
relief of chronic pain syndromes [18]. 
1.8 Treatment of traumatic spinal cord injury  
Despite advances in pre-hospital care, medical and surgical management, and 
rehabilitation approaches, many SCI sufferers still experience substantial neurological 
disability [13]. Cell therapy is a research area to assess the nature of the 
pathophysiology of secondary SCI. Different approaches using different types of cells 
have been studied for many years, including stem cells and non-stem cells. Stem cell 
therapy contains cell sources such as embryonic stem cells, neural progenitor cells, 
bone marrow mesenchymal cells. Non-stem cells include olfactory ensheathing cells 
and Schwann cells [13, 47]. Cellular transplantation after SCI has several aims: to 
bridge any cysts or cavities; to replace dead cells (for example, to provide new 
neurons or myelinating cells); and to create a favorable environment for axon 
regeneration. Cellular therapeutic interventions include:  transplantation of peripheral 
nerves, transplantation of Schwan cells, transplantation of olfactory nervous system 
cells, transplantation of embryonic CNS tissue, transplantation of embryonic 
stem/progenitor cells, transplantation of adult stem/progenitor cells, transplantation of 
engineered stem/progenitor cells, transplantation of activated macrophages and 22 
 
transplantation of stem cell-derived oligodendrocyte progenitor cells [48, 49]. 
Molecular therapies after SCI have several aims: to protect neurons from secondary 
cell death; to promote axonal growth; and to enhance conduction. Molecular 
therapeutic interventions include: neuroprotective therapies, therapies that enhance 
remyelination or enhance conduction such as potassium channel blocker that can 
improve axonal conduction, delivery of growth factors, such as brain-derived 
neurotrophic factor (BDNF), and basic fibroblast growth factor, delivery of cAMP or 
small GTPases. Researchers have also investigated modulation of interactions with 
myelin inhibitors and extracellular matrix modifiers [48].  
Pharmacological treatments also have been one of the methods in this area, 
their strategies focus on the control of secondary injury processes. This control 
primarily includes lipid peroxidation (LP), the salvage of as much white matter as 
possible and suppression of fibrous scarring by local inhibition of collagen 
biosynthesis and basement membrane deposition [14, 50]. 
Nanomedicine and biomaterial design strategies have been devised to promote 
axonal extension through a site of injury and provide the extracellular environment to 
prevent the inhibitory molecules during the acute and chronic phase of SCI. There are 
a variety of nanostructured scaffolds which can make an environment to enhance the 
chance of axon elongation and neuron regeneration. Many experts agree that the 
greatest hope for treatment of spinal cord injuries will involve an approach that 
integrates biomaterial scaffolds, cell transplantation, and molecule delivery. Some 23 
 
biomaterial strategies for spinal cord injuries include silicone, chitosan and collagen 
[51]. Peptide amphiphiles (PA) are synthetic molecules that self- assemble into 
nanofibers [52]. A family of PAs has been demonstrated to self-assemble reversibly 
into a nanofiber network, which result in the formation of aqueous gels through pH 
changes. The PA fibers can then be reversibly polymerized to enhance their stability. 
These two switchable events controlling the formation of supramolecular structure and 
polymerization produce a remarkably versatile material [53]. Few treatments are 
currently available or are even being investigated in clinical trials that address 
neurological impairment following traumatic SCI [54]. Therefore, there is a dire need 
for effective treatments that can reduce neurological deficit and improve a patient’s 
quality of life following SCI. Unfortunately despite all the efforts have been done so 
far in this area,  no satisfactory therapy is currently available [55]. 
1.9 IKVAV-peptide 
1.9.1 IKVAV, its function and role in the spinal cord 
Self-assembling nanofibers are bioactive and biocompatible materials which 
are used in neuronal tissue engineering [56]. Laminin is a major basement membrane-
specific glycoprotein [57]. So far, five alpha, three beta, and three gamma chains have 
been identified, and at least 15 isoforms are formed by various combinations of each 
subunit. Laminin-1, consisting of three chains designated alpha 1, beta1, and gama1, 
has diverse biological activities. Several active sequences of laminin-1 have been 
identified using synthetic peptide approaches. An Ile-Lys-Val-Ala-Val (IKVAV) 24 
 
sequence located on the C-terminal end of the long arm of the alpha1 chain promotes 
cell adhesion, neurite outgrowth, angiogenesis, collagenase IV production, and tumor 
growth [58]. It has been shown that some of the analogs, in which the lysine and 
isoleucine residues of the IKVAV peptide were substituted with different amino acids, 
promoted cell attachment, but none of the analog peptides showed neurite outgrowth 
activity comparable to that of the IKVAV peptide. These results suggest that the lysine 
and isoleucine residues are critical for the biological functions of the IKVAV peptide 
[59]. Tube formation is a multi-step process induced by laminin. An RGD-containing 
sequence in the A chain of laminin through an integrin receptor on the endothelial cell 
induces their attachment to the protein while a YIGSR site in the B1 chain induces 
cell-cell interactions and the resulting tube formation. Also the laminin-derived 
synthetic peptide YIGSR contains sufficient information to induce single endothelial 
cells to form ring-like structures surrounding a hollow lumen, the basic putative unit in 
the formation of capillaries [60]. Tumor cells attach, degrade, and migrate through 
basement membranes as they metastasize. Laminin, a major glycoprotein of basement 
membranes, promotes the metastatic activity of tumor cells by stimulating the 
attachment and migration of the cells and their secretion of collagenase IV. A 
synthetic peptide of 19 amino acids (Cys-Ser-Arg-Ala-Arg-Lys-Gln-Ala-Ala-Ser-Ile-
Lys-Val-Ala-Val-Ser-Ala-Asp -Arg) from the sequence of the A chain of laminin 
increases experimental metastases of the lungs by murine melanoma cells. The peptide 
is active when injected either intravenously or intraperitoneally. The peptide increased 
collagenase IV activity, a key enzyme in the breakdown of basement membranes, to 25 
 
the same extent as laminin. This peptide represents an active site on laminin for 
promotion of the metastatic phenotype and generates a probe for studying the 
regulation of malignant activities [61]. Neurons from peripheral and central nervous 
tissue as well as from established cell lines respond to low concentrations of laminin 
with rapid extension of axon-like processes. Two sites on laminin have been identified 
which stimulate neurite outgrowth, the major site residing at the end of the long arm of 
laminin. Recently laminin has been cloned and sequenced allowing for synthetic 
peptides to be prepared and tested for biological activity. Antisera against synthetic 
peptides corresponding to A and to B1 chain sequences at the end of the long arm can 
partially inhibit laminin-mediated neurite outgrowth. A 19 amino acid synthetic 
peptide (CSRARKQAASIKVAVSADR) from the long arm of the laminin A chain is 
capable of stimulating neuronal-like process formation to almost the same extent as 
laminin and competes with laminin for stimulation of neurite outgrowth [62]. A 19-
mer peptide (designated PA22-2), from just above the carboxyl globule on the long 
arm of the A chain, was found to promote cell adhesion, spreading, migration, and 
neurite outgrowth. By testing smaller sequences within the 19-mer peptide, a 
constituent pentapeptide, IKVAV (Ile-Lys-Val-Ala-Val), was identified as the active 
site for cell adhesion and neurite outgrowth. These data suggest that this sequence is 
one of the principle sites in laminin which regulate cellular behavior [63]. Peptide 
amphiphile molecules are designed to form cylindrical nanofibers that display to cells 
in the spinal cord the laminin epitope IKVAV (isolucine-lysine-valine-alanine-valine) 
at nearly van der Waals density. The nanofibers containing the IKVAV epitope have 26 
 
been demonstrated to promote regeneration of both descending motor fibers and 
ascending sensory fibers through the lesion site. These nanofibers also resulted in 
significant behavioral improvement, reduced cell death, increased number of 
oligodendrocytes and reduced astrogliosis [64]. Self-assembling peptide scaffolds 
consist of alternative amino acids that contain 50% charged residues. These peptides 
are characterized by their periodic repetition of alternating ionic hydrophilic and 
hydrophobic amino acids that spontaneously form beta sheet structures. These beta 
sheets have distinct polar and non-polar surfaces. They are also buoyant in aqueous 
solution and readily transportable to different environments. Upon exposure to 
aqueous solution with neutral pH, ions screen the charged peptide residues and 
alanines (which form the non-polar surfaces of the beta sheets) of different beta sheets 
pack together as a result of their hydrophobic interactions in water. This gives rise to 
double-layered beta sheet nanofibers, a structure that is found in silk fibroin from 
silkworm and spiders. Thus the final self-assembly step to create the peptide scaffold 
takes place under physiological conditions [65]. The nanofibers that self-assemble in 
aqueous media place the bioactive epitope on their surfaces at van der Waals packing 
distances. These nanofibers bundle to form 3D network and produce a gel-like solid. 
The nanofibers have high aspect ratio and high surface areas, 5 to 8 nm in diameter 
and width length of hundreds of nanometers to a few micrometers. Thus, the 
nanofibers that form around cells in 3D present the epitopes at an artificially high 
density relative to a natural extracellular matrix [66].  
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1.9.2 Transmembrane spanning peptides 
Membrane proteins form key nodes in mediating the cell's interaction with the 
surroundings, which is one of the main reasons why the majority of drug targets are 
membrane proteins [67].  Membrane-spanning domains are composed mainly of alpha 
helices, whose associations within the cellular membrane are generally governed by 
electrostatic and van der Waals interactions [68]. Helix-helix interactions are 
important for the folding, stability, and function of membrane proteins [69]. α-Helical 
membrane proteins fulfill many vital roles in all living cells and constitute the majority 
of drug targets [70]. They play numerous and diverse functions, including water and 
solute transport, signal transduction and integration, enzymatic activity, and anchorage 
of cytoskeletal or extracellular components. Membrane proteins account for about one 
third of all proteins encoded in the human genome and make up more than half of all 
current drug targets [71, 72]. Rationally designed nanomedicines have the potential to 
overcome obstacles to tissue regeneration by allowing presentation of bioactive 
molecules for longer periods while guiding the regenerative processes.  We 
incorporated the laminin-derived bioactive sequence, IKVAV, to the cell-spanning 
peptide to increases the half-life of one or more bioactive molecules within the site of 
injury may improve regeneration of nerve tissue following spinal cord injury (SCI).  
1.9.3 IKVAV-peptide for treatment of spinal cord injury 
Peptide amphiphile (PA) molecules that self-assemble from aqueous solution 
into cylindrical nanofibers that display bioactive epitopes on their surfaces were used 28 
 
as a therapy in a mouse model of spinal cord injury [64].  IKVAV PA (a negatively 
charged PA incorporating the neuroactive pentapeptide epitope from laminin, 
isoleucine-lysine-valine-alanine-valine (IKVAV)) nanofibers are known to inhibit 
glial differentiation of cultured neural stem cells and to promote neurite outgrowth 
from cultured neurons. In vivo treatment with the PA after SCI reduces astrogliosis, 
cell death, and increases the number of oligodendroglia at the site of injury. 
Furthermore, the nanofibers promote regeneration of both descending motor fibers and 
ascending sensory fibers through the lesion site. Treatment with the PA also causes 
significant behavioral improvement. These observations demonstrate that it is possible 
to inhibit glial scar formation and to facilitate regeneration after SCI using bioactive 
three-dimensional nanostructures displaying high densities of neuroactive epitopes on 
their surfaces [64]. 
 IKVAV-peptide used in this experiment is a membrane spanning peptide 
expressing the IKVAV epitope on spinal cord. With this method of administration, the 
neurotrophic motif can be presented without the use of extraneous materials such as 
gelatin or nanofibers. Furthermore, our previous work has demonstrated that once 
injected into tissue, the peptide remains at the site of the injection with a long half-life. 
This assured us that these peptides could provide a sustained signal within the lamina 
to enhance repair of neurons and restore function to the injured spinal cord. 
Regeneration of nerve function can be stimulated by proper presentation of the neurite 
stimulating IKVAV-peptide at the site of the injury [64].  29 
 
1.10 Statement of objectives and investigational rationale 
1.10.1 Objectives 
The goal of the project was to demonstrate that the peptide IKVAV conjugated 
with a membrane spanning peptide acts by influencing the spinal cord’s response to 
injury. Further, the research determined the effects and safety of the IKVAV-peptide 
when injected into the site of injury in mice. The final objective was to document the 
effects of IKVAV-peptide on neurons and astrocytes at the site of spinal cord injury 
and on peripheral skeletal muscle following spinal cord injury in mice. Finally, the 
effects of a single injection of IKVAV-peptide were determined by blinded 
observation of injured mice and measurement of their BBB scores at 28 days 
following injury.  
1.10.2 Rationale 
In the present study, IKVAV-peptide treated mice revealed the largest number 
and size of active neurons compared with all other treatment groups (p<0.05), thus 
indicating that the IKVAV-peptide may induce a progressive, active phase in neurons 
to stimulate normal function and even regeneration. However, in the other treatment 
groups, reduction of neuron size characterized with shrunken cell cytoplasm may have 
represented necrotic and apoptotic phases of SCI. The rationale for use of the IKVAV 
motif is based upon its ability to stimulate neuron regeneration. By attaching this 
peptide to a membrane spanning peptide we hypothesized that the sustained 30 
 
presentation of IKVAV following injury would improve functional recovery following 
spinal cord injury.  
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Abstract 
Efficacy of local treatment with a membrane spanning peptide expressing the 
isoleucine-lysine-valine-alanine-valine (IKVAV) epitope on spinal cord regeneration 
was assessed following compression injury in Balb-c mice. The day after 
hemilaminectomy and compression injury, mice were treated with one of the 
following: IKVAV, IKVAV-peptide, peptide or mannitol/saline (vehicle). Functional 
improvement in movement was assessed daily and spinal cord segments were studied 
histologically 28 days after injury. The Basso, Beattie, and Bresnahan (BBB) score for 
locomotion in the IKVAV-peptide group increased by 5.4 (25%) points, the IKVAV 
and peptide groups by approximately 1 point (5%) and the mannitol group by 4 points 
(19%). The number of protoplasmic astrocytes in the IKVAV-peptide group was 
significantly increased compared to IKVAV, mannitol, and normal groups but not 
with the peptide group (p<0.001). Neuron and muscle bundle size were also increased 
significantly (p<0.05 and p<0.007, resp.) in the IKVAV-peptide group compared to 
other treatment groups. The observations in this study demonstrated that it is possible 
to promote functional recovery after spinal cord injury (SCI) using bioactive IKVAV 
presenting cell spanning peptides. 
Background 
Cell penetrating peptides designed to deliver drugs and respond to changes in 
pH were first reported by Summerton et al. [73]. Later versions of this approach to 
drug delivery have included pH-sensitive membrane peptides (pHLIPs) derived from 33 
 
the bacterioehodopsin C helix [74] and rationally designed pH activated peptides [75]. 
These technologies have generally been applied to delivery of macromolecules into 
tumor cells. However, these molecules have potential for enhancing the delivery and 
increasing the efficacy of biomolecules for other diseases. The role of biomolecules in 
the regenerative process is well established and several peptides have been identified 
that show promising results in preclinical studies [73-77]. Clinical applications remain 
limited due to a lack of delivery systems that allow sustained presentation of the 
bioactive molecules within the site of injury. Rationally designed nanomedicines have 
the potential to overcome obstacles to tissue regeneration by allowing presentation of 
bioactive molecules for longer periods while guiding the regenerative processes. Thus 
combining a delivery system that increases drug half-life of one or more bioactive 
molecules within the site of injury will improve regeneration of nerve tissue following 
spinal cord injury (SCI). We have recently developed and tested a novel drug delivery 
system based on previously published pH sensitive cell membrane spanning peptides 
[75]. Further we incorporate the laminin-derived bioactive sequence, isoleucine-
lysine-valine-alanine-valine (IKVAV), because along with its backbone peptide 
amphiphile (PA) it has been shown to reduce astrogliosis, reduce neuron cell death, 
increase the number of oligodendrocytes, promote regeneration of both descending 
motor fibers and ascending sensory fibers, and improve behavioral function [78]. In 
culture, bone marrow stromal cells not only proliferate and adhere well, but will also 
yield more neurons when induced to differentiate into neurocytes on IKVAV peptide 
nanofiber gel [79]. Simple IKVAV peptide, laminin or control PA which do not 34 
 
contain neuroactive biotopes have not been able to suppress astrocytic differentiation 
[66, 78]. Therefore, we hypothesized the biological effect of our IKVAV-peptide is 
different to previous reports of the method of action of the IKVAV motif alone, it may 
promote neuron regeneration following SCI to improve neurological outcome, and 
stimulate neuron regeneration [78]. In preliminary experiments, the non-neurotrophic 
portion of the peptide (without IKVAV) will adhere to tissue and remain at the site of 
injection with a long half-life of more than 24 hours. We hypothesized the IKVAV-
peptide combination will allow sustained presentation of the IKVAV motif within the 
site of injury of SCI without requiring additional extraneous chemicals or constructs 
such as a hydrogel, it would stimulate increased neuron regeneration, and reduced 
glial scarring leading to improved function in mice with SCI. 
Loss of the neuronal Nissl bodies has been shown five minutes after a weight 
drop SCI in rodents. The electron micrographs of neurons in gray matter have also 
shown fragmented nucleus and condensed bodies, along with shrunken cell bodies 
[80]. In addition, following incomplete SCI, atrophy of skeletal muscle occurs and it is 
replaced by intramuscular fat [81, 82]. These markers of spinal cord deterioration 
following SCI (glial scar, astrocytes, Nissl bodies, fragmented nuclei, condensed 
bodies, shrunken cell bodies, and muscle bundle atrophy) were used in this report to 
determine the effect of IKVAV attached to a membrane spanning peptide administered 
topically to the injured spinal cord in mice. 35 
 
The model chosen for determining the effect of this novel Nano peptide was 
the clip compression injury model. All existing models of SCI in mice produce injury, 
but none of them could produce an initial impact plus persisting compression, other 
than the graded model of clip compressive SCI in the mouse used here [78]. Mortality 
reported to be less than 10% during the injury process and the 0% incidence of 
mortality during the post-injury neurological assessment period were also considered 
advantages of this novel model [77]. 
Self-assembling peptide-based three-dimensional biomaterials are being 
developed for therapeutic applications that include cell adhesion, proliferation, and 
differentiation [66, 79, 83]. These materials have some appealing properties for 
application in regenerative medicine because they mimic the structure of the ECM, are 
reabsorbable, allow biofunctionalization, and can be injected directly into the lesion 
[84]. In our study, the transmembrane-spanning peptide presents the neurotrophic 
biotope IKVAV in the ECM without extraneous materials, such as gelatin or 
nanofibers, in order to retain the IKVAV signal at the site of injury for a prolonged 
period to sustain the signal for the neurons to regenerate and to prevent scar formation. 
Materials and Methods 
Animal care and mouse spinal cord injury 
All animal procedures were undertaken in accordance with the Public Health 
Service Policy on Human Care and Use of Laboratory Animals. All procedures were 
approved by the Institutional Animal Care and Use Committee (IACUC) at Oregon 36 
 
State University. Thirty healthy skeletally mature Female Balb-c mice (10 weeks of 
age) were divided into five groups of 6 animals each with a nonsurgical group of 
normal mice and surgical treatment groups including: vehicle (mannitol 0.5mg/ml), 
control (IKVAV 0.5mg/ml), control (peptide, AELLLELELLELELLL, 0.5mg/ml), 
and treatment (IKVAV-peptide, AELLLELELLELELLLAIKVAV, 0.5mg/ml). All 
peptides were synthesized with 95% purity. We anticipated needing six mice per 
treatment group based on analysis of preliminary data; however, this number was 
increased to account for animal loss, unrelated to treatment. Animals were 
anesthetized with isoflurane inhalant (4-5% induction, 1-2% maintenance). After 
laminectomy, at the level of T12 vertebral segment, the spinal cord was compressed 
dorsoventrally by the extradural application of a 24 g modified aneurysm clip for 1 
minute [85]. Following spinal cord injury, the incision was closed using metal staples 
(Autosuture, Norwalk, CT). Postoperatively, animals were kept in cages placed on a 
circulating water pad (80 °F) to prevent hypothermia and 1.0 milliliter injection of 
saline was administered once daily subcutaneously (s.c.) to prevent dehydration. 
Blocked bladders were manually emptied (by finger pressing the bladder over the 
pelvic region) two to three times daily throughout the study. We used 
phenoxybenzamine (5-10 mg/kg, orally) to address urine retention and bladder 
distention. Phenoxybenzamine is used to reduce internal urethral sphincter tone. It 
may also be used for urethral spasm secondary to bacterial urethritis [86]. 
Buprenorphine was given (0.05 mg/kg, s.c., twice daily) for analgesia in the event that 
the animal showed signs of discomfort (such as chewing, anorexia, and other signs of 37 
 
pain). Enrofloxacin was administered once daily in the event of hematuria or self-
mutilation (5mg/kg,) orally for 5 to 7 days. Mice that exhibited any hind limb 
movement less than 24 hours following the injury were excluded from the study. 
Peptide injection 
IKVAV-peptide (0.5 mg/ml, 1% Phosphate Buffered Saline, 2.5% mannitol 
solution) or other treatments including control peptides at equal molar concentrations, 
were administered 24 hours after injury using tuberculin syringes with a fine (25 
gauge) needle. Under isoflurane anesthesia, the skin sutures were removed and the site 
of injury (subcutaneous portion) was exposed. A micropipette was inserted just under 
the granuloma formed at the site of injury dorsally on the spinal cord, and 10 μl of the 
IKVAV-peptide solution (approximately 5 μg total) or other treatments were applied 
to the injury site. The needle was carefully withdrawn and the wound was closed. For 
all experiments, the investigators were kept blind to the identity of the treatment 
groups. 
Basso, Beattie, and Bresnahan open-field locomotion score 
To assess behavioral recovery from SCI, the Basso, Beattie, and Bresnahan 
(BBB) open-field locomotion score was observed using the BBB Locomotor Rating 
Scale [87, 88]. For examination, the mice were placed individually in an open field on 
a non-slippery surface. The 22-point (0–21) BBB scale was used to assess hind limb 
locomotor recovery including joint movements, stepping ability, coordination, and 
trunk stability. A score of 21 indicates unimpaired locomotion as observed in 38 
 
uninjured mice whereas a score of 0 indicates complete absence of voluntary 
movement. The tests were performed by two examiners who were blinded to the 
animal’s treatments. BBB tests were performed every day after injury till the end of 
the study (28 days). 
Animal tissue acquisition and preparation 
On day 28, animals were euthanized with an overdose intraperitoneal 
pentobarbital (beuthanasia-D , Schering-Plough Animal Health Corp., Union, NJ) 
100mg/kg (0.2 ml/mouse) and the spinal cords were removed after complete 
laminectomy at the site of the injury and immediately placed in 2% buffered formalin. 
The spinal cords were kept in the refrigerator overnight and then transferred to the 
electron microscopic laboratory for routine tissue processing. Semi-thin sections 
(0.5μm) were cut using a Sorvall MT2-b (Norwalk Connecticut, USA) microtome for 
light microscopic observations and then ultrathin sections (60 nm) were cut with a 
diamond knife and put on 100 mesh copper grids for transmission electron 
microscopic observation using Philips CM/12 STEM (Eindhoven, Netherlands). 
Muscle preparation 
Hamstring and quadriceps muscles were dissected from all groups and fixed in 
2% buffered formalin for 24 hours. Segments were embedded in paraffin and 
processed routinely for light microscopic evaluation of 5 μm sections stained with 
hematoxylin and eosin. 39 
 
Neuron and muscle bundle size quantification 
The computer software ImageJ (Wayne Rasband, National Institutes of Health 
(NIH), USA) was used to measure the neuron and muscle size. We used micrometer 
(μm) as a unit for measuring the surface of each neuron and each muscle bundle. 
Protoplasmic astrocyte quantification 
Astrocytes were counted in 3 fields of each semi-thin section for each mouse at 
400 magnification using calibrated ocular lens with Lattice lines. 
Statistical analysis 
Two-way ANOVA and general linear model were used to analyze the data. 
Differences in BBB scores, body weight between group means, and protoplasmic 
astrocytes numbers were analyzed using two-way ANOVA. Neuron and muscle size 
means were identified using linear model test and a significance level of p < 0.05. 
Statistical analysis was carried out using the open source statistical programming 
arrangement ’R’ [89]. 
Results 
To assess the functional recovery of the spinal cord and measure the basis of 
the functional recovery following injury, several outcome parameters were used 
including BBB score, histological and electron microscopy. At 4 weeks after SCI, 
IKVAV-peptide mice displayed a significant improvement in neurological status 
(p<0.05), whereas none of the other treatment groups were significantly altered from 40 
 
their immediate postoperative status (Figure 2.1, Supplementary Table 2.1). Large 
variation in the mannitol vehicle treated group resulted in no significant difference 
between it and any of the other groups (p>0.05). 
Effect of the IKVAV-peptide on Protoplasmic Astrocytes 
As seen in Figure 1, IKVAV-peptide significantly improved neurological 
recovery following acute SCI, with improvements in motor function evident as early 
as 4 weeks following treatment. At 4 weeks following SCI, ocular counting of light-
microscopic sections of injured spinal cords identified increased numbers of 
protoplasmic astrocytes in the IKVAV-peptide treatment group compared to IKVAV, 
normal and mannitol groups (p<0.001) (Figure 2.2). However, IKVAV-peptide was 
not significantly different from the peptide treated group (p>0.05) (Supplementary 
Table 2.2). 
Effect of the IKVAV-peptide on Neuron Size and Neuron Cell Death 
Injury-induced apoptosis can be detected from hours up to days following 
injury and may contribute to neurological dysfunction [90]. We used ImageJ software 
to measure the size of the neurons in each of the treatment groups to determine 
whether the injection of the IKVAV-peptide could support cellular regeneration of the 
motor neurons. The images of all sections were taken using a light microscope 
equipped with a digital camera (DFC280 Model, Leica Microsystems Ltd) [91], with 
400X magnification. There was a significant increase in the size of the neurons of the 
gray matter in the IKVAV-Peptide mice compared to the other four groups (p<0.05) 41 
 
(Figure 2.3) (Supplementary Table 2.3). Neuron reactivation was seen in the gray 
matter of the spinal cord at the site of injury. Neuron degeneration and death were 
detected using light microscope (LM) and transmission electron microscope (TEM) 
micrographs. The characteristics of neuronal death were examined, included apoptosis 
and necrosis. These included shrunken cell bodies with intact cell membranes, 
chromatolysis evidence such as dispersed Nissl’s substances, and finally a loss of 
these cellular organelles throughout the cytoplasm along with loosely dispersed 
nuclear chromatin. Few expanded empty spaces were also noticed between the neuron 
cell bodies in IKVAV, peptide, and mannitol mice. Using LM and TEM images we 
observed 1.4 to 2.4-fold larger neurons in the IKVAV-peptide group (Figure 2.3, panel 
A1-2). 
Effect of the IKVAV-peptide on Muscle Size 
Each section was photographed using digital camera connected to the light 
microscope, with 400X magnification. To measure the muscle bundles we used 
ImageJ software to assess the degree to which SCI with and without treatment can 
affect muscle morphology. The results of this measurement indicated that the size of 
muscle bundles in IKVAV-peptide treated group was significantly increased compare 
with IKVAV and peptide groups (p<0.05) but not with normal and mannitol treated 
mice (p>0.05) (Figure 2.4, Supplementary Table 2.4). Control treated groups showed 
identified atrophied muscle bundles with considerable amount of muscular fat (Figure 
2.4, C-D). 42 
 
Effect of the IKVAV-peptide on body weight 
The body weight was measured for each mouse daily, using a digital scale. 
Significant differences in the change in body weight was identified only between 
IKVAV-peptide and mannitol mice (p<0.05, 19.9 ± 4.1 versus 13.2 ± 2.0, resp.). 
Discussion 
The pathophysiology of acute SCI involves primary and secondary 
mechanisms of injury [17, 25, 29, 92]. These mechanisms involve the initial 
mechanical damage leading to secondary injury processes that contribute to further 
tissue loss, functional impairment, and lesion size increase [21, 90]. Secondary injury 
involves the apoptotic and necrotic death of neurons and glial cells [93, 94]. The 
microscopic evaluation of neuron death within the lesion site in this study is consistent 
with other studies, which have described similar amounts of apoptosis and necrotic 
death after SCI [94-99]. Although SCI leads to neuronal death, we have seen small 
numbers of surviving neurons with normal intact structure within the lesion site, which 
is consistent with other studies using the clamp model [100]. In the present study, 
IKVAV-peptide treated mice revealed the largest number and size of active neurons 
compared with all other groups (p<0.05), thus indicating that the IKVAV-peptide 
induced an progressive active phase in these neurons to regain their normal function. 
However, in the other groups, reduction of neuron size characterized with shrunken 
cell cytoplasm may have represented necrotic and apoptotic phases of SCI, which is in 
agreement with other reports at 28 days post-injury [99].  43 
 
The SCI was induced with the clamp crush method which is a technique 
relevant and similar to clinical SCI in humans [101]. In order to mimic clinical delays 
in definitive treatment while the patient is stabilized following SCI, we also chose to 
administer treatment approximately 24 hours following surgery. Recovery was 
incomplete 28 days following treatment, however, IKVAV-peptide treatment 
promoted significant functional improvement that can be attributed to the observed 
differences in neuronal cell death and astrocyte function. Although reactive astrocytes 
may form a glial scar that can, in some cases, prevent axonal regeneration, they also 
have a crucial role in wound healing and functional recovery following SCI. 
Emergence and migration of reactive astrocytes have a prominent role in the repair of 
injured tissue and the restoration of motor function in the subacute phase of healing 
neuronal tissue (before completion of the glial scar) [102]. Loss of astrocyte activities 
during the cellular response to SCI can lead to gross functional deficits and failure of 
functional recovery and suggest that reactive astrocytes not only protect tissue but also 
preserve function after SCI [15, 103].  
In this experiment, IKVAV-peptide treatment improved neurological function 
and resulted in an increase in the number of astrocytes. Our results support the positive 
role of astrocytes in promoting neuron regeneration across the site of injury. 
Interestingly, the peptide-treated group had a similar increase in the number of 
astrocytes at the site of injury compared to the IKVAV-peptide group. However, 
neurological function was not improved in this group suggesting that IKVAV must be 
present on the peptide to achieve successful restoration of movement. The reason for 44 
 
similar numbers of astrocytes between these groups is unknown and further 
investigation into the mechanism of astrocyte induction with the membrane spanning 
peptide is warranted. Compelling evidence indicates that formation of a glial scar 
inhibits axonal regeneration 4 weeks after SCI [104]. In agreement with this finding; 
we observed functional behavioral scores reached a plateau from week 3 to week 4. 
Reactive astrocytes divide and slowly migrate into CNS injuries, eventually to fill in 
the vacant space and most of a glial scar is made up of astrocytes. Whether astrocytes 
inhibit or promote neuronal growth has been investigated [105]. Multiple models have 
demonstrated the molecular composition of the glial scar and production of inhibitory 
molecules by astrocytes are contributing factors for regenerative failure of axons 
following injury [106-110]. Yet other studies suggest there is a promoting effect of 
astrocytes on axonal regeneration [102-104, 111]. The in vitro evidence for the ability 
of astrocytes to promote or inhibit axon regeneration is conflicting. In our study, mice 
treated with IKVAV and a transmembrane spanning peptide or a transmembrane 
spanning peptide alone, had increases in astrocytes at the site of injury. In contrast to 
the peptide alone stimulated astrogliosis without neuronal recovery, IKVAV-peptide 
treatment produced neuronal recovery which occurred along with astrogliosis. Further 
research is warranted to determine why this difference in functional outcome with a 
similar increase in astrocytes occurred. However, treatment success with IKVAV-
peptide was definitive by our measures. 
A major concern for patients following SCI is skeletal muscle atrophy. In 
rodent models of SCI, skeletal muscle atrophy is associated with smaller muscle 45 
 
bundles and an increase in intramuscular fat (IMF). Moreover, IMF continues to 
increase over time in incomplete SCI [82]. IKVAV-peptide treatment prevented 
muscle atrophy as evinced by increased muscle mass, larger muscle bundle size, and 
decreased IMF. Further, functional improvement in IKVAV-peptide mice indicates the 
re-innervation of locomotory muscles.  
Our results are significant because none of the mice in our study received 
physical therapy or exercise of any kind other than being allowed free movement 
within their cage; yet, mice treated with the IKVAV-peptide did not develop the 
muscle atrophy and increase in IMF seen in the other treatment groups. Increases in 
muscle mass are possible even years after injury if the appropriate mode and intensity 
of exercise are utilized even without spinal cord neuron recovery [111, 112]. 
Unilateral neuromuscular electrical stimulation (NMES) can evoke hypertrophy in the 
knee extensor and adjacent skeletal muscle groups and is associated with a reduction 
in IMF in human beings with chronic SCI. However, it seems rebuilding muscles after 
SCI needs more time in order to obtain the increased muscle mass that occurs with 
physical therapy.  
Time is an important factor for recovery following injury. We followed the 
mice for 28 days post-SCI using a similar model as Tysseling et al which reported 
IKVAV PA-injected group displayed significant behavioral improvement at 5 weeks 
and thereafter, compare to the control group [64].Surprisingly, treatment with our 
IKVAV-peptide resulted in significant functional recovery observed approximately 46 
 
one week after SCI and reached a plateau in improvement of function at week 4. In 
addition to marked improvement in BBB scores at week 1, several mice displayed 
self-mutilation. A total of 13 mice chewed on their feet or tails with the majority of the 
mice in the IKVAV-peptide and mannitol treatment groups (6 mice, mannitol: 4 mice, 
peptide: 2 mice and IKVAV: 1 mouse). Self-mutilation indicated to us the mice may 
have been regaining feeling in their extremities. In addition to this, because SCI 
interrupts neuronal circuits which control the bladder function [39], some of the mice 
were not able to urinate. Interestingly, in the last week of the study most of the 
IKVAV-peptide treated mice regained their ability to urinate (4/6) suggesting again re-
innervation with restoration of function.  
Our observations are similar to kinematic studies of locomotors recovery 
following SCI in rats with the thoracic clip compression model reporting that during 
the 6-week post injury period, a significant amount of spontaneous locomotor 
recovery occurred in 80% of the rats with a return of well-defined locomotor hind 
limb pattern. However, substantial residual abnormalities persisted up to 6 weeks after 
SCI including postural deficits [113]. Interestingly, in the last week of the study most 
of the peptide- IKVAV treated mice regained their ability to urinate (4/6) suggesting 
again re-enervation with restoration of function. 
Further research using greater numbers of animals and following the recovery 
and neuron regeneration over a longer period of time such as 3 to 6 months is 
warranted to determine whether the improvements seen in the short term using 47 
 
IKVAV-peptide are maintained later in the regenerative process. The results suggest a 
role for cell spanning peptides as a platform nanotechnology for the treatment of 
injury or disease. 
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Figure legends 
Figure 2.1. IKVAV-peptide mice had a significant change in neurological status by 28 
days following spinal cord compression injury whereas none of the other treatment 
groups were significantly altered. There is a large amount of variation in the mannitol 
vehicle treated group and this resulted in no significant difference between this group 
and any of the other groups (p>0.05). IKVAV-peptide group has the highest 
improvement in mean BBB score compared to all other groups measured by one way 
ANOVA (p=0.0067) with Dunn’s multiple comparison post-test. Standard error (SE) 
has been shown to describe the mean accurately. 
Figure 2.2. The number of protoplasmic astrocytes at the injury site in IKVAV-
peptide treated mice is significantly increased compared to all other groups except the 
peptide group (p<0.001). IKVAV-peptide box plot shows normal distribution of 
protoplasmic astrocyte means compare to all other groups. 
 
Figure 2.3. Mean neuron size was significantly larger in the IKVAV-peptide group 
compared to all other groups 4 weeks after SCI (p<0.05) and exceed the mean size of 
neurons of non-surgical controls. The pictures presented in A-D shows the comparison 
between different groups at light (1) and electron microscope (2) level. In IKVAV-
peptide group (A), the activated large neurons are obvious and actually larger 
compared to Normal (B), however, in control groups IKVAV (C), Peptide (D), and 
Mannitol (E) the neurons are shrunken and in some cases pyknotic. 
 
Figure 2.4. There is a significant increase in the means of IKVAV-peptide (A) muscle 
bundle size compared to IKVAV (C) and Peptide (D) (p<0.007) but not to Normal (B) 
and Mannitol (E) groups. The pictures presented in A-D shows the comparative 
differences between representative groups. 
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Group  Mean Standard Error  Minimum Median  Maximum 
Normal  0 0 0 0 
IKVAV-peptide 5.4 1.4 0  4  12 
Mannitol 4.2 2.04 0  1.5  16 
Peptide 1.7 1.09 0  1  7 
IKVAV 1 0.54 0  1  4 
Table 2.1: Change in BBB scores over time 
Group  Mean Standard Error  Minimum Median  Maximum 
Normal 13.1 0.57 11.7  12.7  15 
IKVAV-peptide 18.2 0.88 16  18  21.3 
Mannitol 14.2 2.38 4  15.7  24 
Peptide 19.1 4.96 7.3  18  37.3 
IKVAV 16.1 2 12  14.3  21.7 
Table 2.2: Protoplasmic astrocytes 
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Group  Mean Standard Error  Minimum Median  Maximum 
Normal 0.2 0.02 0.1  0.2  0.3 
IKVAV-peptide 0.3 0.05 0.2  0.3  0.5 
Mannitol 0.1 0.04 0.05  0.08  0.4 
Peptide 0.2 0.06 0.04  0.1  0.4 
IKVAV 0.1 0.03 0.03  0.1  0.2 
Table 2.3: Neuron size 
Group  Mean Standard Error  Minimum Median  Maximum 
Normal 0.8 0.15 0.5  0.6  1.2 
IKVAV-peptide 0.9 0.23 0.3  1  1.5 
Mannitol 0.6 0.12 0.2  0.6  0.9 
Peptide 0.2 0.04 0.1  0.2  0.4 
IKVAV 0.2 0.06 0.1  0.2  0.4 
Table 2.4: Muscle size 
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Abstract 
A transmembrane-spanning peptide linked to the IKVAV peptide known to have a long 
half-life and the peptide motif, isoleucine-lysine-valine-alanine-valine (IKVAV) was used to 
evaluate neuronal effects on recovery from spinal cord injury (SCI) in a vascular clamp model of 
injury in mice. The IKVAV-peptide protein was applied directly to the spinal cord at the site of 
injury 24 hours following post-trauma. Because the membrane spanning portion of the peptide 
adheres to tissue upon injection with a half-life of more than 24 hours, we hypothesized that the 
bioactive IKVAV sequence will provide a sustained regenerative signal at the sight of injury. 
Light and electron microscopy of spinal cord sections were used to determine the effect of 
mannitol, IKVAV-peptide, peptide alone, and IKVAV alone applied directly to the spinal cord at 
the site of injury compared to mice not receiving SCI or treatment. Treatment with IKVAV-
peptide following SCI resulted in an increased number of protoplasmic astrocytes and large 
active motor neurons crossing the site of the SCI and regeneration of muscle bundles in 
peripheral skeletal muscle in addition to improvement in neurological function. 
Keywords: IKVAV-peptide, neurons, protoplasmic astrocytes, muscle bundles, light 
micrographs, electron micrographs. 
Introduction  
Spinal cord injury is a debilitating condition that stimulates complex cellular and 
molecular interactions in the spinal cord at the site of injury and results in altered cellular 
morphology in an attempt to repair the initial damage. These interactions include contributions 
from inflammatory cell activation, reactive astrocytes and the production of both growth 57 
 
promoting and inhibitory extracellular molecules [114]. The use of nanostructures in medicine is 
an emerging field with the potential to enhance cellular recovery from trauma. To assess the 
feasibility of using a peptide based nanostructure to facilitate regeneration of damaged spinal 
tissue, it is necessary to determine the cellular responses within the lesion at the site of injury. 
Biological analysis of SCI in mouse models has pointed to both necrotic and apoptotic 
mechanisms of cell death after injury [115]. Electron micrographs of neurons in gray matter 
following SCI have shown fragmented nuclei and condensed bodies along with shrunken cell 
bodies. Neuronal and glial apoptosis following SCI can contribute to neurological dysfunction, 
paresis and paralysis [99] . Spinal cord injury also results in glial reaction which recruits 
microglia, oligodendrocyte precursors, meningeal cells, astrocytes and stem cells. Most of these 
cell types produce molecules that have been shown to be inhibitory to axon regeneration.  
Activated astrocytes after SCI exhibit different morphology, and the morphological 
characteristics are distinct at different stages. Activated astrocytes migrate and eventually form a 
glial scar at the site of the injury which inhibits axon regeneration and recovery of normal 
function. The glial scar that forms following spinal injury is an evolving structure, with different 
cells arriving and participating at different stages, to create a final structure that is predominantly 
astrocytic. This astrocyte response to injury is referred to as reactive gliosis (more glia) but in 
fact, in most instances of SCI, the actual amount of glial cell division is relatively small and 
confined to the immediate penumbra surrounding the lesion core [104, 116-119]. Astrocytes 
form the majority of the scar and may be responsible for inhibition of neuron regeneration across 
the site of injury.  58 
 
The laminins are a family of glycoproteins that provide an integral part of the structural 
scaffolding of basement membranes in almost every animal tissue. Each laminin is a heterotrimer 
assembled from α, β, and γ chain subunits. Laminin is secreted and incorporated into cell-
associated extracellular matrices. The laminins can self-assemble, bind to other matrix 
macromolecules, and have unique and shared cell interactions mediated by integrins, 
dystroglycan, and other receptors. Through these interactions, laminins critically contribute to 
cell differentiation, cell shape and movement, maintenance of tissue phenotypes, and promotion 
of tissue survival. Laminin 1 is one of the isoforms of laminin which consists of three chains, α1, 
β1 and γ1. IKVAV is an active sequence of laminin-1 which is located in the C-terminal end of 
the long arm of the α1 chain which promotes cell adhesion, neurite outgrowth, angiogenesis, 
collagenase IV production, and tumor growth [60, 61, 120-122]. In a recent study [64], it has 
been shown that treatment with IKVAV PA (peptide amphiphile) following SCI, reduced 
astrogliosis and subsequent glial scar as well as cell death, cell death. IKVAV also increased the 
number of oligodendroglia, promoted regeneration of descending motor fibers and ascending 
sensory fibers and resulted in significant behavioral improvement in mice.  
Skeletal muscle atrophy results from denervation and consequently disuse and 
immobilization in both complete and incomplete SCI. Within weeks post-injury, skeletal muscle 
cross-sectional area (CSA) can be as low as 30% to 50% compared with un-injured controls. 
Moreover, skeletal muscle atrophy has been associated with increasing infiltration of 
intramuscular fat (IMF) [81, 82, 123]. Skeletal muscle atrophy is a common adaptation after 
spinal cord injury (SCI) that results in numerous health-related complications [123]. The 
detrimental effects of atrophy also include altered body composition [124],cardiovascular disease 
[125],osteoporosis [126]and increased incidence of metabolic syndrome [127].  59 
 
Our hypothesis was that, the novel IKVAV-peptide conjugate can be used to enhance the 
reactivation and regeneration processes at the site of injury following SCI by presenting and 
sustaining the IKVAV motif within the site of the injury. Therefore, the specific purpose of this 
study was to evaluate the functional recovery by means of BBB score and histological 
observations in mice treated with the IKVAV-peptide following SCI in a mouse clip-
compression model. We analyzed nerve cells, astrocytes and glial scar formation in the injured 
spinal cord. In addition, we determined the effect of IKVA-peptide on the rate of muscle atrophy 
following SCI.  
Materials and Methods 
Experimental Design  
All animal procedures were undertaken in accordance with the Public Health Service 
Policy on Human Care and Use of Laboratory Animals. All procedures were approved by the 
Institutional Animal Care and Use Committee (IACUC). Five groups of female Blab-c mice (10 
weeks of age) weighing 24-25 grams were used in this study. Animals were anesthetized with 
isoflurane (4-5% induction, 1-2% maintenance). After hemilaminectomy, all groups underwent 
T12 spinal cord segment compression dorsoventrally by the application of a 24 g modified 
aneurysm clip for 1 min [85]. Twenty-four hours after injury, each group received one of the 
following solutions applied directly to the spinal cord: IKVAV-peptide, IKVAV, peptide and 
mannitol. Following surgery, the skin was sutured using metal staples (Autosuture, Norwalk, 
CT). Post –operatively, animals were kept in cages placed on circulating water pad (80◦ F) to 
maintain body temperature. A 1.0 ml injection of saline was given once daily subcutaneously 
(s.c.). Distended urinary bladders were manually expressed (by finger pressing the bladder over 60 
 
the pelvic region) two to three times daily throughout the study. In the event that animal showed 
signs of discomfort such as chewing, anorexia and other signs of pain, buprenorphine was 
administered (0.05 mg/kg, s.c., twice daily). Enrofloxacin was administered once daily in the 
event of hematuria (5mg/kg,) orally for 5 days and, if animals self-maimed, was given orally for 
at least 7days at this same dose. Mice that exhibited any hind limb movement 24 hours after the 
injury were excluded from the study. For all experiments, the experimenters were kept blind to 
the treatment protocol of each group of animals. 
Peptide injection  
Peptide (1%PBS (Phosphate Buffered Saline), 2.5% mannitol solution) or other 
treatments were injected 24 hours after injury using sterile micropipette. Under isoflurane 
anesthesia, the skin autoclips were removed and the injury site was exposed. The micropipette 
was inserted just under the granuloma formed at the site of injury which contained 10 µl of the 
diluted peptide solution (5 µg of IKVAV-peptide) or other control solution. At the end of 
injection the needle was carefully withdrawn and the wound was closed.  
Animal tissue acquisition and preparation  
On the day 28, animals were euthanized with a 0.2 ml/mouse intraperitoneal Beuthanasia-
D 
1and the spinal cords were removed and immediately placed in 2% buffered formalin.  The 
spinal cords were kept at 4° C overnight and  transferred to the karnovsky fixative [128] before 
placing at 4° C for 3 hours. The tissue was rinsed four times in buffer (Cacodylate, 0.1 M, pH 
7.2) for 30 minutes each and then incubated in osmium tetroxide (OsO4) for 1 hour at 25°C. The 
                                                            
1 Schering-Plough Animal Health Corp., Union, NJ 
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dehydration procedures were performed using 50% acetone, 70% acetone twice and 100% 
acetone each for 30 minutes, respectively.  
After dehydration, the spinal cords were infiltrated using acetone: spur resin mixture first 
with a proportion of 3:1 for 30 minutes following by 1:1 and 1:3 each for one hour and then 
100% spurs for overnight on a rotating wheel. After 24 hours, each spinal cord was embedded in 
the flat mound and kept at 63 ᵒC overnight. Semi-thin sections (0.5µm) were cut using  Sorvall 
MT2-b 
2for light microscopic observations and then (0.06 µm) ultrathin sections were cut with a 
diamond knife and put on 100 mesh copper grids for transmission electron microscopic study 
using Philips CM/12 STEM
3. 
Muscle preparation 
 Hamstring and quadriceps muscles were dissected from all groups and fixed in 2% 
buffered formalin for 24 hours and processed routinely for light microscopic evaluations with 
sections of 5 microns.  
Neuron and muscle size quantification  
The computer software ImageJ
4 was used to measure the neuron and muscle size of each 
mouse using images obtained from the above sections. A micrometer fitted into the microscope 
was used to calibrate image size, along with magnification strength. We used µm as a unit for 
measuring the surface area of each neuron and each muscle bundle.  
                                                            
2 Norwalk Connecticut, USA 
 
3 Eindhoven, Netherlands 
 
4 Wayne Rasband, National Institutes of Health (NIH),USA 
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Protoplasmic astrocytes quantification  
Astrocytes were counted in 3 fields of each semi-thin section for each mouse at 400X 
magnification using calibrated ocular lens with Lattice lines
5.  
Statistical Analysis  
Two-way ANOVA and generalized linear model were used to analyze the data. 
Differences in BBB scores, body weight between group means, and protoplasmic astrocytes 
numbers were analyzed using a two-way ANOVA. Neuron and muscle cross-section means were 
identified using a linear model test and a significance level of p < 0.05. Statistical analysis was 
carried out using the open source statistical programming arrangement ’R’ [89]. 
Results 
Light microscopic observations using semi-thin sections revealed that the main 
morphological difference between IKVAV-peptide treated mice and the other treatment groups 
was the size of the motor neurons. IKVAV-peptide treated mice (Figure 3.1, B&C) had neurons 
larger in cross-sectional size than the normal group (Figure 3.1, A) which did not have SCI or 
treatment (p<0.05). On the other hand, the other three treatment groups (IKVAV alone, peptide 
alone, mannitol) had smaller neurons with shrunken cell cytoplasm compared to the normal mice 
(p>0.05).  
                                                            
5 Leica ocular lens, German, Optic Company 
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Among the three surgical  groups (IKVAV alone, peptide alone, mannitol), the peptide 
group had severely shrunken neurons; however mannitol and IKVAV groups had small neurons 
that were not as small as the peptide group but still not equal in size to the normal control group 
(Figure 3.2).  
At the electron microscopic level, a survey of ultrathin sections (0.06 µm) revealed that 
in the IKVAV-peptide group, all the motor neurons were active consisting of active cytoplasmic 
organelles such as extensive rough endoplasmic reticulum (RER), free ribosomes, developed 
Golgi complex and mitochondria surrounding a euchromatic nucleus (Figure3.3). These 
ultrastructural characteristics were similar in appearance to the normal control group (Figure 
3.4), however, IKVAV-peptide treated neurons were much larger and active than normal 
controls confirming observations made at the light microscopic level. In the treated control 
groups (IKVAV alone, peptide alone, mannitol), motor neurons were non-active with shrunken 
cytoplasm having dispersed segmented RER and loosely associated nuclear chromatin in their 
nuclei (Figure 3.5). Particularly in these mice, the nuclear membranes were not folded unlike the 
normal and IKVAV-peptide treated groups. In addition, the outer nuclear membranes lacked 
ribosomal attachments in most areas of the three treated control groups (Figure 3.6). 
In this experiment, counting the number of protoplasmic astrocytes in each group 4 
weeks following SCI and treatment, demonstrated that the IKVAV-peptide treated mice had 
more protoplasmic astrocytes surrounding the motor neurons compared to the normal untreated, 
mannitol and IKVAV groups (P<0.001). However, the protoplasmic astrocytes were similar in 
number in both IKVAV-peptide and peptide groups (P>0.05). Observations of the proximal hind 
limb muscles (quadriceps and hamstrings) revealed that in the IKVAV-peptide treated group, 64 
 
muscle bundles were thicker in comparison to the IKVAV alone- and peptide alone-treated 
groups (P<0.05), but not with mannitol-treated and normal untreated mice muscle (P>0.05). In 
addition, the intramuscular fat seen between bundles occupied less space in IKVAV-peptide 
group than in the other groups (Figure3.7). Locomotion score scale, Basso, Beattie, Bresnahan 
(BBB), showed statistically significant functional improvement in the IKVAV-peptide treated 
group which corresponded with the light and electron microscopic findings (P<0.0067). There 
were some deaths during the study in each of the four treatment groups. Some of the mice were 
euthanized due to self-mutilation:  5 mice in IKVAV-peptide group, 2 mice in the peptide only 
group, 3 mice in the mannitol group and 2 mice in the IKVAV only group. Some of the mice 
died overnight at some time during the first two weeks following SCI and the cause was not 
identified on necropsy: 1 in the peptide group and 2 in IKVAV group. In addition, one mouse 
died within 5 minutes of rupture of the bladder while it was manually expressed. 
Discussion 
The laminin-derived IKVAV sequence was incorporated into peptide amphiphile (PA) in 
order to enhance neural attachment, migration and neurite outgrowth from inactive neurons 
following SCI [129].To explore the cellular changes related to this improvement, light and 
electron microscopic evaluation of neurons, protoplasmic astrocytes and muscle bundles was 
undertaken. In this study, IKVAV-peptide treatment resulted in neurite reactivation in gray 
matter, evinced by functional improvement using BBB locomotion score scale and the 
morphological changes that demonstrated the slow but impressive functional progress following 
treatment.  65 
 
Neuronal death is normal during nervous system development but it is an abnormal 
consequence of brain and spinal cord injury with two distinct forms of cell death, apoptosis and 
necrosis [130]. Apoptosis and necrosis of neurons in the mice not treated with IKVAV-peptide 
following spinal cord injury in this study is consistent with previous reports using this mouse 
model of SCI [90, 93-95, 99, 131, 132]. The reactivation of neurons in IKVAV-peptide treated 
mice compared to the treatment control groups was evidenced by the significantly increased size 
of the neurons, abundant organelle presence, and nuclear membrane folding. Previous research 
has demonstrated that the absence of astrocytes in both white and gray matter following SCI 
results in unsuccessful axon regeneration and that the presence of immature fibrous astrocytes in 
the white matter and reactive protoplasmic astrocytes in the gray matter of the spinal cord within 
the site of injury in the early phase are necessary for axon regeneration [15, 129, 133]. 
Protoplasmic astrocyte enumeration in the IKVAV-peptide group demonstrated increased 
number of astrocytes compared to all other groups including the normal control group. Our 
results support the evidence that, at least in the subacute phase, the existence of astrocytes is 
necessary for reactivation of neurons and subsequent regeneration of axons; and further, that 
their absence can markedly exacerbate neuron and glial cell degeneration [102, 103, 134, 135].  
Reports of successful spinal cord therapies have correlated neurological functional 
recovery with reduced muscle atrophy following treatment [123, 130, 136]. Significant 
functional improvement was observed in IKVAV-peptide treated mice compared to the other 
treatment groups, along with reduced muscle atrophy (increased muscle bundle mass and 
decreased intramuscular fat) compared to IKVAV, peptide or mannitol treatment controls. 
Further investigation of IKVAV-peptide and the mechanism involved in preservation of muscle 
mass following SCI is warranted.  66 
 
Conclusions 
Investigators were blinded to evaluate the effects of the novel nanostructure IKVAV-
peptide and assess its efficacy. Our findings demonstrate that the novel IKVAV-peptide injected 
at the site of spinal cord injury may improve the functional behavior of neurons and astrocytes at 
the site of injury which could result in improved outcome in other species including humans.  
The neurons in IKVAV-peptide group became more active presumably to compensate for 
deficits following injury as evinced by more functional organelles compared to all groups 
including neurons found in normal spinal cord tissue. These findings revealed that a peptide that 
includes a cell spanning moiety and the neurite-stimulating motif IKVAV is a unique structure 
that has the potential to improve the recovery among patients with SCI. However, these results 
are preliminary and this research would benefit from larger numbers of animals and longer 
duration of assessment following treatment to develop better and complete understanding of the 
applications and limitations of this technology. Therefore, further investigation is warranted to 
evaluate the full potential of this treatment approach in SCI and other conditions where peptide 
mediated regeneration is possible. 
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Figure legends 
Figure 3.1. Photomicrograph of untreated normal mouse (A) showing a portion of ventral horn of 
the gray matter. A few relatively large motor neurons with pale nuclei and dark nucleoli can be 
seen between cellular processes (large arrows). Protoplasmic astrocytes are also evident (small 
arrow). Photomicrographs of IKVAV-peptide treated mouse (B&C) revealing very large active 
motor neurons (arrows) surrounded by many nerve fibers (arrows head) in both pictures. Many 
protoplasmic astrocytes are visible (small arrows). In Figure C a cross section of spinal canal 
lining by large cuboidal cells can also be seen (C). Toluidine Blue X400. 
Figure 3.2.In this photomicrograph (A) of peptide treated control mouse most of the motor 
neurons are atrophied (arrows). Photomicrograph showing only the gray matter portion of the 
spinal cord in mannitol treated control mouse (B). All motor neurons are atrophied (arrows) 
compare with figures 1A &B (normal and IKVAV-peptide). This photomicrograph (C) shows a 
portion of ventral horn of gray matter between white matter (WM) from IKVAV treated control 
mouse. Note the atrophied motor neurons (arrows). Toluidine Blue X400. 
 
Figure 3.3. Electron micrograph of IKVAV-peptide treated mouse (A) showing association of 
protoplasmic astrocyte (PA) with active motor neuron (MN). Some myelinated fibers are also 
visible (arrow). Uranyl acetate and lead citrate X3400.  
Electron micrograph of IKVAV-peptide treated mouse at higher magnification (B). Two active 
motor neurons can be seen, each with large euchromatic nucleus and prominent electron dense 
nucleolus. Many cisternae of RER (arrows), active Golgi complexes (G) and mitochondria (*) 
are also evident throughout the perikaryon. Note the highly folded nuclear membranes in both 
cells. Compare to untreated normal mouse (Figure 3.4) these motor neurons are much larger. 
Uranyl acetate and lead citrate X7100. 
 
Figure3.4. Electron micrograph of untreated normal mouse. In this micrograph (A), a 
protoplasmic astrocyte (PA) can be seen in close association with a motor neuron (MN). Motor 
neuron has a large euchromatic nucleus with prominent dense nucleolus surrounded by small 
portion of cytoplasm rich in Nissl substances, RER at arrows and free ribosomes (Circle). A few 
mitochondria (M) can also be seen. Uranyl acetate and lead citrate X7100.  
This electron micrograph (B) shows active motor neuron of untreated normal mouse with 
extensive Nissl substances (arrows) and mitochondria (M) at higher magnification. Infolding of 
nuclear membranes is extensive with ribosomes associated outer membrane. Uranyl acetate and 
lead citrate, X8800. 
 
 
Figure3.5. In peptide treated control mouse (A) most of the motor neurons are degenerated and 
atrophied which resulted in presence of a few motor neurons in gray matter (arrow). Uranyl 
acetate and lead citrate X2650.  
Electron micrograph of peptide treated control mouse at higher magnification (B) shows two 
atrophied motor neurons surrounded by few myelinated nerve fibers. In addition to small 
perikaryonic portions, dispersed and loosely associated nuclear chromatin are present. Uranyl 
acetate and lead citrate X5600.  68 
 
This electron micrograph from peptide treated control mouse at higher magnification shows 
obviously a shrunken motor neuron with dispersed nuclear chromatin. In all control groups 
including this control (C), the nuclear membranes are not folded compared with normal and 
IKVAV-peptide treated groups. The outer nuclear membrane is also lack of ribosomes in most 
areas (arrows) Uranyl acetate and lead citrate X7100. 
 
Figure 3.6. Electron micrographs of motor neuron in mannitol treated mouse (A) revealing 
another atrophied neurons. The small cytoplasmic portion is mostly occupied by degenerated 
mitochondria (M). Uranyl acetate and leas citrate X8800. 
Electron micrograph of a shrunken motor neuron of IKVAV treated control mouse (B). Even at 
this magnification the cellular cytoplasm is not apparent. Myelinated fiber (large arrow) and non-
ribosomal outer membrane attachment (small arrow). Uranyl acetate and lead citrate X15000.  
Note the lack of nuclear membrane infolding in all control groups. 
 
Figure3.7. Comparative photomicrographs showing cross sections of the hind limb muscles in 
different groups, normal (A), IKVAV-peptide (B), mannitol (C), peptide (D), IKVAV (E) of 
mice at the same magnification. Note the presence of thicker bundles in IKVAV-peptide group 
compared to IKVAV and peptide groups. H & E, X400. 
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Chapter IV 
 
4.1 Summary 
The Role of Animal Model 
Clip compression injury resembles spinal cord injury caused by pressure to the spinal 
cord. The spinal cord becomes ischemic and mimics common clinical injuries and outcomes 
[137]. Investigations of possible cures and of ways to alleviate the hardships of traumatic SCI 
include those of interventions that attenuate or overcome the secondary injury cascade, enhance 
the endogenous repair mechanisms, regenerate axons, replace lost cells, and rehabilitate. These 
investigations have led to the creation of laboratory animal models of the different types of 
traumatic human SCI and components of the secondary injury cascade. However, no particular 
model completely addresses all aspects of traumatic SCI. Importantly, as researchers in this area 
move toward clinical trials to alleviate the hardships of traumatic SCI, there is a need for 
standardized small and large animal SCI models as well as quantitative behavioral and 
electrophysiological assessments of their outcomes so that investigators testing various 
interventions can directly compare their results and correlate them with the molecular, 
biochemical, and histological alterations [138]. In our experiment mouse model was used which 
had some limitations. One of the limitations was the small size of the spinal cord segments which 
was somehow difficult to be handled for histological procedures. These limitations mainly 
include the mushy characteristic of the spinal texture which was overcome by pouring of fixative 
over the cord and the small diameter of the spinal segments. From the beginning of the 74 
 
experiment self-mutilation was one of the main reasons for euthanizing the mice. Although we 
used a collar to prevent further self-injuries, this particular device was not successful in 
prevention of self-mutilation. Therefore, larger animal models such as rats or even pigs may 
provide more data for analysis and may enable improved supportive care during recovery when 
sensation is returning and the likelihood of self-mutilation is highest.  
To compress the spinal cord dorsoventrally we had to perform hemilaminectomy and 
remove the dorsal lamina of each vertebra at the site of surgery. After 28 days we noticed 
histologically a bone growth into the spinal cord from the edges of the removed vertebra which 
completely filled the gray matter with bone cells in some of the mice. One of the ideas to 
overcome this problem may be to fill the site of the laminectomy with materials such as gelatin 
or fascia to prevent bone ingrowth.   
Due to the mentioned complications and problems particular to this experiment it may be 
logical to increase the number of mice in each experimental group. In addition, other treatment 
methods need to be explored such as administration of the IKVAV-peptide intravenously instead 
of at the site of injury, at various time points following injury, and potentially multiple 
administrations of the IKVAV-peptide complex to the site of injury. Potential improvement in 
the response to the treatment may be gained by administering the drug prior to the onset of 
secondary spinal cord injury such as within 6 hours of the onset of injury. Another consideration 
may include varying concentrations of the IKVAV-peptide so that an optimal dose and timing as 
well as frequency of administration could be obtained.  
  The results of these preliminary experiments indicate that administration of the 
IKVAV-peptide complex 24 hours following spinal cord injury in an experimental model of 75 
 
injury in mice results in improved functional outcome, increased neuron regeneration, increased 
astrocyte concentration at the site of injury and reduced muscle atrophy at 28 days following 
injury. These findings warrant further investigation of this peptide complex in the treatment of 
acute spinal cord injury.  
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